DATE: 29 August 2012 CONTEXT AND POLICY ISSUES

Size: px
Start display at page:

Download "DATE: 29 August 2012 CONTEXT AND POLICY ISSUES"

Transcription

1 TITLE: Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence DATE: 29 August 2012 CONTEXT AND POLICY ISSUES Acute myocardial infarction (AMI) is one of the most frequent causes of mortality world-wide. 1 AMI is caused by prolonged ischemia resulting from sudden occlusion of a coronary artery due to thrombus formation. 1 ST-segment elevation myocardial infarction (STEMI) is a type of AMI. In STEMI patients ST-segment elevation is observed in the electrocardiogram. Prompt diagnosis of STEMI is important as the benefits of therapy are greater when initiated early. The initial reperfusion generally involves two options: pharmacologic reperfusion by fibrinolysis or mechanical reperfusion by primary percutaneous coronary intervention (PCI). 2 PCI is the preferred choice, if it can be performed in a timely fashion by experienced health care providers. 3 Not all hospitals, however, have PCI facilities and such facilities are generally fewer in rural areas compared to urban areas. 3 The reperfusion therapy used depends on the availability of resources and local practice patterns. 2 STEMI patients are treated with a variety of pharmacologic agents which include thrombolytic agents such as streptokinase and tenecteplase; anticoagulants such as unfractionated heparin and enoxaparin; and anti-platelets such as aspirin and clopidogrel. 4 The aim of this report is to review the clinical effectiveness of dual antiplatelet therapy combined with enoxaparin or unfractionated heparin compared with thrombolytic therapy in patients with STEMI. RESEARCH QUESTION What is the comparative clinical effectiveness of dual antiplatelet therapy combined with enoxaparin or unfractionated heparin versus thrombolytic therapy in patients with ST-elevation myocardial infarction? Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material. It may be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners own terms and conditions.

2 KEY MESSAGE No relevant studies were identified that compared the clinical effectiveness of dual antiplatelet therapy combined with enoxaparin or unfractionated heparin versus thrombolytic therapy in patients with ST-elevation myocardial infarction. METHODS: Literature Search Strategy A limited literature search was conducted on key resources including MEDLINE, PubMed, The Cochrane Library (2012, Issue 8), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 01, 1998 and August 15, Selection Criteria and Methods Table 1: Selection Criteria Population Intervention Comparator Outcomes Study Designs Adult patients with ST segment elevation myocardial infarction Dual antiplatelet therapy (clopidogrel and ASA) combined with enoxaparin or unfractionated heparin Thrombolytic therapy (streptokinase, urokinase, alteplase, reteplase, tenecteplase) Reduction in thromboembolic events, morbidity/mortality, congestive heart failure, bleeding risk, cardiac adverse events, other adverse events Health technology assessments, systematic reviews and metaanalyses, randomized controlled trials (RCT), and non-randomized studies Exclusion Criteria Studies were excluded if they did not satisfy the selection criteria in Table 1; if they were published prior to1998, duplicate publications of the same study, or included in a selected health technology assessment or systematic review and did not provide additional relevant information. Critical Appraisal of Individual Studies No critical appraisal was conducted as no relevant studies were identified. Dual antiplatelet therapy and enoxaparin or UFH for STEMI 2

3 SUMMARY OF EVIDENCE: Quantity of Research Available The literature search yielded 248 citations. Upon screening titles and abstracts, 242 articles were excluded and six potentially relevant articles were selected for full-text review. However, upon further investigation none of the six articles satisfied the inclusion criteria and were excluded. No relevant studies were identified from the grey literature. No relevant health technology assessments, systematic reviews, randomized controlled trials or non-randomized studies were identified. Details of the study selection process are outlined in Appendix 1. References, which did not satisfy the selection criteria and included information regarding the intervention in STEMI patients, may be of interest and are provided in the Appendix 2. Summary of Study Characteristics Summary of Critical Appraisal Summary of Findings Limitations CONCLUSIONS AND IMPLICATIONS FOR DECISION OR POLICY MAKING: PREPARED BY: Canadian Agency for Drugs and Technologies in Health Tel: Dual antiplatelet therapy and enoxaparin or UFH for STEMI 3

4 REFERENCES 1. Wakai AP. Myocardial infarction (ST-elevation). Clin Evid (Online) Diercks DB, Kontos MC, Weber JE, Amsterdam EA. Management of ST-segment elevation myocardial infarction in EDs. Am J Emerg Med Jan;26(1): Larson DM, Duval S, Sharkey SW, Garberich RF, Madison JD, Stokman PJ, et al. Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J May;33(10): Lincoff AM, Cutlip D. Anticoagulant therapy in acute ST elevation myocardial infarction [cited 2012 Aug 23]. In: UpToDate [Internet] Waltham (MA): UpToDate; Available from: Subscription required. Dual antiplatelet therapy and enoxaparin or UFH for STEMI 4

5 APPENDIX 1: Selection of Included Studies 248 citations identified from electronic literature search and screened 242 citations excluded 6 potentially relevant articles retrieved for scrutiny (full text, if available) No potentially relevant reports retrieved from other sources (grey literature) 6 potentially relevant reports 6 reports excluded: -irrelevant comparator (2) -irrelevant condition (2) -other (review articles, editorials) (2) No relevant reports Dual antiplatelet therapy and enoxaparin or UFH for STEMI 5

6 APPENDIX 2: References of Potential Interest (Comparison not Relevant) Larson DM, Duval S, Sharkey SW, Garberich RF, Madison JD, Stokman PJ, et al. Safety andefficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J May;33(10): Yoo SY, Shin DH, Lee JY, Cheong S, Jang JK, Lee C. Clinical outcomes of brief versusprolonged unfractionated heparin infusion after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in the drug-eluting stent era: realworld, single-centre experience. Acta Cardiol Aug;66(4): Heestermans T, Suryapranata H, ten Berg JM, Mosterd A, Gosselink AT, Kochman W, et al. Facilitated reperfusion with prehospital glycoprotein IIb/IIIa inhibition: predictors of complete STsegment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial: correlates of reperfusion before primary PCI. J Electrocardiol Jan;44(1):42-8. Armstrong PW, Gershlick A, Goldstein P, Wilcox R, Danays T, Bluhmki E, et al. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J Jul;160(1):30-5. Buller CE, Pate GE, Armstrong PW, O'Neill BJ, Webb JG, Gallo R, et al. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can J Cardiol [Internet] May 1 [cited 2012 Aug 23];22(6): Available from: Dual antiplatelet therapy and enoxaparin or UFH for STEMI 6

TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines

TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 27 June 2012 CONTEXT AND POLICY ISSUES In 2009, CADTH reviewed the clinical

More information

TITLE: Fall Prevention in Adults with Mental Health and Substance Use Needs: A Review of the Clinical Evidence and Guidelines

TITLE: Fall Prevention in Adults with Mental Health and Substance Use Needs: A Review of the Clinical Evidence and Guidelines TITLE: Fall Prevention in Adults with Mental Health and Substance Use Needs: A Review of the Clinical Evidence and Guidelines DATE: 11 January 2012 CONTEXT AND POLICY ISSUES: Approximately 30 to 40 percent

More information

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06

More information

Portable versus Fixed X-ray Equipment: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines

Portable versus Fixed X-ray Equipment: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines TITLE: Portable versus Fixed X-ray Equipment: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines DATE: 22 February 2016 CONTEXT AND POLICY ISSUES Portable X-ray has been an useful

More information

TITLE: Diabetic Diets for Frail Elderly Long-Term Care Residents with Type II Diabetes Mellitus: A Review of Guidelines

TITLE: Diabetic Diets for Frail Elderly Long-Term Care Residents with Type II Diabetes Mellitus: A Review of Guidelines TITLE: Diabetic Diets for Frail Elderly Long-Term Care Residents with Type II Diabetes Mellitus: A Review of Guidelines DATE: 15 June 2015 CONTEXT AND POLICY ISSUES People with type 2 diabetes, also known

More information

TITLE: Dental Cleaning and Polishing for Oral Health: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines

TITLE: Dental Cleaning and Polishing for Oral Health: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines TITLE: Dental Cleaning and Polishing for Oral Health: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines DATE: 24 September 2013 CONTEXT AND POLICY ISSUES Dental practitioners (dentist,

More information

TITLE: Rivaroxaban for the Treatment of Deep Vein Thrombosis: A Review of the Guidelines

TITLE: Rivaroxaban for the Treatment of Deep Vein Thrombosis: A Review of the Guidelines TITLE: Rivaroxaban for the Treatment of Deep Vein Thrombosis: A Review of the Guidelines DATE: 04 December 2012 CONTEXT AND POLICY ISSUES Deep vein thrombosis (DVT) and acute pulmonary embolism (PE) are

More information

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

Il punto sulla terapia antitrombotica nelle sindromi coronariche acute

Il punto sulla terapia antitrombotica nelle sindromi coronariche acute Santa Margherita Ligure TIGULLIO CARDIOLOGIA 2012 16-17 Febbrajo 2012 Il trattamento dell infarto miocardico acuto ad ST spraslivellato: dal territorio al laboratorio di emodinamica Il punto sulla terapia

More information

SIGN 93 Acute coronary syndromes. A national clinical guideline Updated February 2013

SIGN 93 Acute coronary syndromes. A national clinical guideline Updated February 2013 Help us to improve SIGN guidelines - click here to complete our survey SIGN 93 Acute coronary syndromes A national clinical guideline Updated February 2013 Evidence KEY TO EVIDENCE STATEMENTS AND GRADES

More information

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor

More information

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Time to Treatment is critical for STEMI patients For patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan

More information

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline David Zhao, MD, FACC, FSCAI Professor of Medicine and Cardiac Surgery Harry and Shelley Page Professor in Interventional Cardiology

More information

6.3. Management 6.3.1. Routine Measures

6.3. Management 6.3.1. Routine Measures ACC/AHA 2004 Practice Guidelines for STEMI 6.3. Management 6.3.1. Routine Measures 6.3.1.1. Oxygen Supplemental oxygen should be administered to patients with arterial oxygen desaturation (SaO2 less than

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

The summary of findings was prepared from the abstracts of the relevant information.

The summary of findings was prepared from the abstracts of the relevant information. Title: Non-Invasive Continuous Positive Airway Pressure (CPAP) for the Management of Acute Respiratory Distress in Pre-Hospital and Rural Community Settings: Clinical and Cost Effectiveness and Guidelines

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014 CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014 e 55 0495 2 Emergency Department (ED)- 1 Emergency Department Throughput Median time from

More information

έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν

έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν ΝΠθ ζζάθδκνσθϋ λδκν έΰκ μνεδν ιωθκ κεκη δεάμνι λδεάμ έΰζβν έκ,νσϊίί κν1γν λδζέκνβί1γ Α Α φ ; έζ δκμννένσθόμ ηί δεόμνκλ δκζόΰκμ, θν δ γθ άμνγνκλ /εάμ ΚζδθδεάμΝ λωεζδθδεάμν ένivus Scientific Director, Mediolanum

More information

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015 Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?

More information

Thrombolytics (Reteplase, Tenecteplase) Rpa/Tnk and Adjunctive Heparin

Thrombolytics (Reteplase, Tenecteplase) Rpa/Tnk and Adjunctive Heparin PRESENTATION Vials of reteplase 10 units for reconstitution with 10ml water for injection. Vials of tenecteplase 10,000 units for reconstitution with 10ml water for injection, or 8,000 units for reconstitution

More information

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of

More information

CAUSES AND PREVENTION OF CARDIORESPIRATORY ARREST

CAUSES AND PREVENTION OF CARDIORESPIRATORY ARREST CAUSES AND PREVENTION OF CARDIORESPIRATORY ARREST B1 Objectives To understand: The causes of cardiorespiratory arrest in adults How to identify patients at risk The role of a Medical Emergency Team The

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die

More information

Title: Bladder Scanner Use Prior to Catheterization: A Clinical Review

Title: Bladder Scanner Use Prior to Catheterization: A Clinical Review Title: Bladder Scanner Use Prior to Catheterization: A Clinical Review Date: 21 April 2008 Context and policy issues: Patients with urine retention, neurogenic bladder or elderly patients in the long-term

More information

Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH

Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH PAUL N. CASALE, M.D., F.A.C.C. Chief, Division of Cardiology and Medical Director of Cardiology, Lancaster General Hospital

More information

Journal of the American College of Cardiology Vol. 42, No. 7, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.

Journal of the American College of Cardiology Vol. 42, No. 7, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30. Journal of the American College of Cardiology Vol. 42, No. 7, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00917-3

More information

Canadian Journal of Cardiology 27 (2011) 529 533. Editorial

Canadian Journal of Cardiology 27 (2011) 529 533. Editorial Canadian Journal of Cardiology 27 (2011) 529 533 Editorial From Primary to Secondary Percutaneous Coronary Intervention: The Emerging Concept of Early Mechanical Reperfusion With Delayed Facilitated Stenting

More information

KEITH ELLIS, M.D., JAMES E. TCHENG, M.D., SHELLY SAPP, M.S., ERIC J. TOPOL, M.D., F.A.C.C., and A. MICHAEL LINCOFF, M.D., F.A.C.C.

KEITH ELLIS, M.D., JAMES E. TCHENG, M.D., SHELLY SAPP, M.S., ERIC J. TOPOL, M.D., F.A.C.C., and A. MICHAEL LINCOFF, M.D., F.A.C.C. Mortality Benefit of Beta Blockade in Patients with Acute Coronary Syndromes Undergoing Coronary Intervention: Pooled Results from the Epic, Epilog, Epistent, Capture and Rapport Trials KEITH ELLIS, M.D.,

More information

TITLE: Extension Tubing Changes for Peripherally Inserted Central Catheters: A Review of the Clinical Evidence and Guidelines

TITLE: Extension Tubing Changes for Peripherally Inserted Central Catheters: A Review of the Clinical Evidence and Guidelines TITLE: Extension Tubing Changes for Peripherally Inserted Central Catheters: A Review of the Clinical Evidence and Guidelines DATE: 21 October 2015 CONTEXT AND POLICY ISSUES Vascular access devices (VADs)

More information

TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines

TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 01 December 2009 CONTEXT AND POLICY ISSUES: Post-traumatic stress disorder

More information

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent

More information

New Oral Anticoagulants in Children: Should They Be Prescribed For Special (Off Label) Situation? No

New Oral Anticoagulants in Children: Should They Be Prescribed For Special (Off Label) Situation? No : Should They Be Prescribed For Special (Off Label) Situation? No Alan D. Michelson, M.D. Professor of Pediatrics and Professor of Medicine Harvard Medical School Director, Center for Platelet Research

More information

INTRODUCTION: DISCUSSION:

INTRODUCTION: DISCUSSION: 82 Mayer Goldberg ALTEPLASE: THE CLOT-BUSTER Mayer Goldberg INTRODUCTION: The human body is defined by many complex and inconsistent characteristics. For example, the body forms blood clots in traumatic

More information

ESC PCI Guidelines: / Sigmund Silber et al. 1

ESC PCI Guidelines: / Sigmund Silber et al. 1 For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction

More information

THE ROLE OF BETA-BLOCKERS IN THE MANAGEMENT AFTER MYOCARDIAL INFARCTION

THE ROLE OF BETA-BLOCKERS IN THE MANAGEMENT AFTER MYOCARDIAL INFARCTION THE ROLE OF BETA-BLOCKERS IN THE MANAGEMENT AFTER MYOCARDIAL INFARCTION Dr. Nani Hersunarti, SpJP(K) Department of Cardiology and Vascular Medicine Faculty of Medicine Universitas Indonesia National Cardiovascular

More information

Postoperative Myocardial Infarction: Diagnosis and Management

Postoperative Myocardial Infarction: Diagnosis and Management Postoperative Myocardial Infarction: Diagnosis and Management Todd M. Brown, MD, MSPH Chief Fellow Division of Cardiovascular Diseases December 9, 2008 CHEST PAIN NON-ANGINAL UNSURE ANGINAL STABLE ANGINA

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

National Medicines Information Centre

National Medicines Information Centre National Medicines Information Centre VOLUME 11 NUMBER 4 2005 ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie For personal use only. Not to be reproduced without

More information

National Hospital Quality Measures Acute Myocardial Infarction (Heart Attack) (AMI-1) Aspirin at Arrival. (AMI-2) Aspirin Prescribed at Discharge

National Hospital Quality Measures Acute Myocardial Infarction (Heart Attack) (AMI-1) Aspirin at Arrival. (AMI-2) Aspirin Prescribed at Discharge National Hospital Quality Measures Acute Myocardial Infarction (Heart Attack) (AMI-1) Aspirin at Arrival Description: Acute myocardial infarction (AMI) patients without aspirin contraindications who received

More information

Trial Design. From the a Southlake Regional Health Centre, Newmarket, Ontario, Canada, b University of Toronto, Toronto, Ontario, Canada,

Trial Design. From the a Southlake Regional Health Centre, Newmarket, Ontario, Canada, b University of Toronto, Toronto, Ontario, Canada, Trial Design Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) Warren J. Cantor, MD, a,b David

More information

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015 Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015 The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS

More information

Surgery and Anti-Coagulation Agents

Surgery and Anti-Coagulation Agents CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Pre-admission clinics and surgical wards Personnel involved in surgical pre-assessment

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

THE RISE AND FALL OF ROUTINE MANUAL THROMBECTOMY FOR ST-ELEVATION MYOCARDIAL INFARCTION

THE RISE AND FALL OF ROUTINE MANUAL THROMBECTOMY FOR ST-ELEVATION MYOCARDIAL INFARCTION THE RISE AND FALL OF ROUTINE MANUAL THROMBECTOMY FOR ST-ELEVATION MYOCARDIAL INFARCTION Vincent Floré, *Stephen P Hoole Department of Interventional Cardiology, Papworth Hospital NHS Foundation Trust,

More information

Bilaga 1. Sökstrategier

Bilaga 1. Sökstrategier Bilaga 1. Sökstrategier Nytta och risk med läkemedel för äldre: perorala antikoagulantia och trombocythämmare Kompletterande sökning Pubmed (översikter utan åldersbegränsning) 2013-04-29 Pubmed via NLM

More information

Implementing a Prehospital 12-Lead Program

Implementing a Prehospital 12-Lead Program Implementing a Prehospital 12-Lead Program Corey M. Slovis, M.D. Professor and Chairman Department of Emergency Medicine Vanderbilt University Medical Center Medical Director, Metro Nashville Fire Department

More information

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne What do the guidelines say? What happens with warfarin

More information

European Resuscitation Council Guidelines for Resuscitation 2005 Section 5. Initial management of acute coronary syndromes

European Resuscitation Council Guidelines for Resuscitation 2005 Section 5. Initial management of acute coronary syndromes Resuscitation (2005) 67S1, S87 S96 European Resuscitation Council Guidelines for Resuscitation 2005 Section 5. Initial management of acute coronary syndromes Hans-Richard Arntz, Leo Bossaert, Gerasimos

More information

Role of elevated heart rate in the development of cardiovascular disease in hypertension

Role of elevated heart rate in the development of cardiovascular disease in hypertension ONLINE SUPPLEMENT Role of elevated heart rate in the development of cardiovascular disease in By Palatini P Department of Clinical and Experimental Medicine University of Padova, Padua, Italy Running title:

More information

CARDIAC RISKS OF NON CARDIAC SURGERY

CARDIAC RISKS OF NON CARDIAC SURGERY CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management

More information

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,

More information

Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC

Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC NAAMA 37 th National Medical Convention September 5 th, 2015 Atherosclerosis Coronary Heart

More information

Antonio Colombo MD on behalf of the SECURITY Investigators

Antonio Colombo MD on behalf of the SECURITY Investigators Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding

More information

1996/1999 ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction

1996/1999 ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction 1996/1999 ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction National Taiwan University Hospital, Department of Internal Medicine Yen-wen Wu, MD / Ai- hsien Lee, MD / Huang-joe

More information

L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001

L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001 L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and

More information

Investor News. PIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016

Investor News. PIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016 Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com American Heart Association (AHA) Scientific Sessions 2016: PIONEER AF-PCI Study

More information

California Health and Safety Code, Section 1256.01

California Health and Safety Code, Section 1256.01 California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program

More information

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Acute Coronary Syndromes: oral antithrombotic therapy Focus on

More information

POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS

POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS POST STENTING DUAL ANTIPLATELET THERAPY DURATION J BAUCUM MD FACC CAROLINA CARDIOLOGY GHS Post Stenting Dual Antiplatelet Therapy When can I stop it? Intracoronary stenting is a frequent intervention for

More information

ESSENTIAL MESSAGES FROM ESC GUIDELINES

ESSENTIAL MESSAGES FROM ESC GUIDELINES ESSENTIAL MESSAGES FROM ESC GUIDELINES Committee for Practice Guidelines To improve the quality of clinical practice and patient care in Europe AMI - STEMI Guidelines FOR the MANAGEMENT OF ACUTE MYOCARDIAL

More information

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory

More information

1 / 174. Xavier Bosch. Authors. Contact person. Dates. Review No. What's new

1 / 174. Xavier Bosch. Authors. Contact person. Dates. Review No. What's new Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-st segment elevation acute coronary syndromes (9819) Review information Authors

More information

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize

More information

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of

More information

Patients with Atrial Fibrillation and PCI or ACS Need Triple Therapy - Practical Guidance

Patients with Atrial Fibrillation and PCI or ACS Need Triple Therapy - Practical Guidance Patients with Atrial Fibrillation and PCI or ACS Need Triple Therapy - Practical Guidance Christopher P. Cannon, M.D. Executive Director, Cardiometabolic Trials, Harvard Clinical Research Institute Cardiovascular

More information

TITLE: Suboxone for Short-term Detoxification: A Review of the Clinical Evidence

TITLE: Suboxone for Short-term Detoxification: A Review of the Clinical Evidence TITLE: Suboxone for Short-term Detoxification: A Review of the Clinical Evidence DATE: 7 September 2011 CONTEXT AND POLICY ISSUES: Opioid dependence is defined as a strong desire to use the substance,

More information

Guideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients

Guideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients Guideline [Optional heading here. Change font size to suit] Document Number # QH-GDL-951:2015 Guideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients

More information

ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction

ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction Journal of the American College of Cardiology Vol. 52, No. 24, 2008 2008 by the American College of Cardiology Foundation and the American Heart Association, Inc. ISSN 0735-1097/08/$34.00 Published by

More information

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf

More information

TITLE: Fondaparinux versus Enoxaparin for Acute Coronary Syndrome: A Review of the Comparative Clinical Effectiveness and Cost-Effectiveness

TITLE: Fondaparinux versus Enoxaparin for Acute Coronary Syndrome: A Review of the Comparative Clinical Effectiveness and Cost-Effectiveness TITLE: Fondaparinux versus Enoxaparin for Acute Coronary Syndrome: A Review of the Comparative Clinical Effectiveness and Cost-Effectiveness DATE: 3 September 2015 CONTEXT AND POLICY ISSUES Acute coronary

More information

Is There A LIfe for DES after discontinuation of Clopidogrel

Is There A LIfe for DES after discontinuation of Clopidogrel Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:

More information

TITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness

TITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness TITLE: Acupuncture for Management of Addictions Withdrawal: Clinical Effectiveness DATE: 09 October 2008 RESEARCH QUESTION: What is the clinical effectiveness of auricular acupuncture in the management

More information

Antithrombotic therapy

Antithrombotic therapy Orthogeriatrics Clinical Summary Document Antithrombotic therapy Topics Preexisting anticoagulation and timing of surgery Reversal of anticoagulation Perioperative thromboprophylaxis When should we be

More information

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

CADTH. Canadian Agency for Drugs and Technologies in Health. Agence canadienne des médicaments et des technologies de la santé

CADTH. Canadian Agency for Drugs and Technologies in Health. Agence canadienne des médicaments et des technologies de la santé Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH March 2013 Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction

Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction original article or in ST-Segment Elevation Myocardial Infarction Paul W. Armstrong, M.D., Anthony H. Gershlick, M.D., Patrick Goldstein, M.D., Robert Wilcox, M.D., Thierry Danays, M.D., Yves Lambert,

More information

TITLE: Urgent Immunochemical Fecal Occult Blood Testing for Patients with Suspected Gastrointestinal Bleeding: Clinical Evidence and Guidelines

TITLE: Urgent Immunochemical Fecal Occult Blood Testing for Patients with Suspected Gastrointestinal Bleeding: Clinical Evidence and Guidelines TITLE: Urgent Immunochemical Fecal Occult Blood Testing for Patients with Suspected Gastrointestinal Bleeding: Clinical Evidence and Guidelines DATE: 28 September 2012 CONTEXT AND POLICY ISSUES Stool sampling

More information

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

Rivaroxaban for acute coronary syndromes

Rivaroxaban for acute coronary syndromes Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following

More information

Improving PCI Benchmark times in a Non-PCI World

Improving PCI Benchmark times in a Non-PCI World Improving PCI Benchmark times in a Non-PCI World May 2011 St David s Georgetown Hospital, Georgetown Texas Margaret Connors BSN, RN, CEN Kirk Sinclair BSN, RN, CEN National Processes/ Mission LifeLine

More information

ACC/AHA Performance Measures

ACC/AHA Performance Measures ACC/AHA Performance Measures ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association

More information

Reperfusion therapy, reocclusion and disease progression in acute myocardial infarction

Reperfusion therapy, reocclusion and disease progression in acute myocardial infarction Reperfusion therapy, reocclusion and disease progression in acute myocardial infarction ISBN/EAN 978-90-9025678-8 Drukwerk: Ipskamp Drukkers B.V., Enschede Ontwerp: O8 grafische vormgeving i.s.m. www.formatters.nl

More information

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:

More information

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily

More information

TITLE: Saline versus Heparin for Maintaining Patency of Central Venous Catheters: A Review of Clinical Effectiveness and Safety

TITLE: Saline versus Heparin for Maintaining Patency of Central Venous Catheters: A Review of Clinical Effectiveness and Safety TITLE: Saline versus Heparin for Maintaining Patency of Central Venous Catheters: A Review of Clinical Effectiveness and Safety DATE: 02 October 2013 CONTEXT AND POLICY ISSUES Central venous access devices

More information